Mads Axelsen

Title: Mads Axelsen: Innovator in Diabetes Treatment

Introduction

Mads Axelsen is a notable inventor based in Virum, Denmark. He has made significant contributions to the field of diabetes treatment through his innovative patents. With a total of 2 patents, Axelsen's work focuses on improving glycaemic control and minimizing weight gain associated with insulin treatment.

Latest Patents

Mads Axelsen's latest patents include a method of treating diabetes mellitus. This method describes a combination of at least a first insulin-like compound and a second insulin-like compound for treating conditions where insulin administration would be beneficial. The combination is designed to achieve beneficial glycaemic control, as determined by the levels of HbA1c in the subject after administration during their largest meal of the day. The beneficial glycaemic control achieved by this combination is superior to that of an equivalent dose of IGlar. Additionally, Axelsen has developed a method for minimizing body weight gain in insulin treatment. This method involves administering an insulin derivative with a substituent containing from 6 to 40 carbon atoms attached to one of its amino acid residues.

Career Highlights

Throughout his career, Mads Axelsen has worked with prominent companies in the pharmaceutical industry, including Novo Nordisk A/S and Novo Nordisk Healthcare AG. His experience in these organizations has allowed him to contribute to advancements in diabetes care.

Collaborations

Mads Axelsen has collaborated with notable individuals in his field, including Thomas Bayer and Signe Rikke Permild, who serves as a Legal Representative.

Conclusion

Mads Axelsen's innovative work in diabetes treatment showcases his commitment to improving patient outcomes. His patents reflect a deep understanding of the complexities of insulin therapy and its effects on glycaemic control and weight management.